

ALLEGATO B

Curriculum formativo, didattico, scientifico e professionale del candidato

Dichiarazione sostitutiva di certificazioni (Art.46,D.P.R.28 dicembre2000n. 445) Dichiarazione sostitutiva dell'atto di notorietà (da sottoscrivere davanti all'impiegato addetto o da presentare con la fotocopia di un documento di identità) (Art.47,D.P.R.28 dicembre2000n. 445)
--

Estremità del bando di selezione	CALL FOR RESEARCH FELLOWSHIP N. 13/2025 – REP.303 /2025 July 8, 2025
Informazioni aggiornate al	July 16, 2025
Nome e Cognome	IZAZMONIRKAMAL
Data di nascita	

Si raccomanda di indicare con precisione tutti gli elementi valutabili ai sensi del bando di selezione (aggiungere o togliere righe secondo necessità).

Esperienza professionale

Periodo	Ente	Principali attività e responsabilità
2019-2024	CSIR-Indian Institute of Chemical Biology	Ph.D. Research in Computational Biology and Drug Design under Dr. Saikat Chakrabarti. Developed MetaDOCK, MLDoV, and DbNSP platforms. Published 8 research papers. Research focus on protein-ligand interactions, molecular docking, machine learning applications in drug discovery.
2024-Present	CSIR-Indian Institute of Chemical Biology	Continued research in computational drug discovery and machine learning applications in biology. Development of web-based computational platforms using Python, PHP, JavaScript, and Flask.

Istruzione, formazione (es. titoli di studio, certificazioni professionali/linguistiche/informatiche)

Data	Titolo/Principali tematiche	Ente
2019-2025	Ph.D. in Computational Biology and Drug Design - Thesis: "Meta-Docking Approach for Protein-Ligand Complexes and Validation Using Machine Learning Techniques"	CSIR-Indian Institute of Chemical Biology (AcSIR)
2016-2018	M.Sc. in Life Science (First Class) - Specialization in Molecular Biology and Biochemistry	Presidency University
2013-2016	B.Sc. in Zoology (First Class) - Foundation in Biological Sciences	Sripat Singh College, University of Kalyani
2019	DBT JRF, ICMR JRF, GATE XL, GATE BT, SET Qualified - National level competitive examinations	Various National Agencies

Publicazioni / Convegni

1. Kamal IM, Chakrabarti S. MetaDOCK: A Combinatorial Molecular Docking Approach. ACS Omega. 2023 Jan 31;8(6):5850-5860.
2. Kamal IM, et al. A Novel spice-antioxidant-based nano-vehicle as alternative AChE inhibitor. J Biomol Struct Dyn. 2023 Aug 28:1-18.
3. Das R, Kamal IM, Das S, Chakrabarti S, Chakrabarti O. MITOL-mediated DRP1 ubiquitylation and degradation promotes mitochondrial hyperfusion in a CMT2A-linked MFN2 mutant. J Cell Sci. 2022 Jan 15;135(2): jcs257808.
4. Maity S, Kamal IM, Das S, Chakraborty J, Chakrabarti S, Chakrabarti O. Endoplasmic reticulum protein FAM134B interacts with DRP1 to maintain mitochondrial morphology. Cell Death and Disease. 2024 Dec 15.
5. Bandopadhyay S, Kamal IM, Padmanaban E, Ghosh DD, Chakrabarti S, Roy SS. Oncogene-mediated nuclear accumulation of lactate promotes epigenetic alterations to induce cancer cell proliferation. J Cell Biochem. 2023 Apr;124(4):495-519.
6. Das R, Maity S, Das P, Kamal IM, Chakrabarti S, Chakrabarti O. CMT2A-linked MFN2 mutation, T206I promotes mitochondrial hyperfusion and predisposes cells towards mitophagy. Mitochondrion. 2024 Jan;74:101825.
7. Kulavi S, Dhar D, Kamal IM, Chakrabarti S, Bandyopadhyay J. EIF4A3 Targeted Therapeutic Intervention in Glioblastoma Multiforme Using Phytochemicals from Indian Medicinal Plants – An Integration of Phytotherapy into Precision Oncomedicine. J Biomol Struct Dyn. 2024 Jan.
8. Biswas N, Kumar K, Mallick P, Das S, Kamal IM, Bose S, Choudhury A, Chakrabarti S. Structural and drug screening analysis of the non-structural proteins of SARS-CoV-2 virus extracted from Indian COVID-19 patients. Frontiers in Genetics. 2021; 12:171.
9. Garg A, Goel N, Abhinav N, Varma T, Achari A, Bhattacharjee P, Kamal IM, Chakrabarti S, Ravichandiran V, Reddy AM, Gupta S, Jaisankar P. Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease. J Biomol Struct Dyn. 2023
10. Patent: MLDoV - Machine Learning based Protein-Ligand complex validation (Final Patent Submitted)

Altre attività scientifiche

Development of MetaDOCK web platform (<http://www.hpppi.iicb.res.in/metadock/index.html>) - Full-stack web application for molecular docking integrating AutoDock4.2, LeDock, and rDOCK algorithms with >90% accuracy in binding pose prediction

Development of MLDoV machine learning pipeline for docking validation using Python, scikit-learn, TensorFlow with integrated SVM, Random Forest, and XGBoost models

Development of DbNSP database and analysis platform for viral protein analysis (<http://www.hpppi.iicb.res.in/covid19/index.php>) built with PHP, MySQL, and Python

Training of 250+ M.Sc. and Ph.D. students in computational drug design and bioinformatics

Expertise in molecular modeling software: SCHRODINGER, GROMACS, NAMD, DS, GLIDE, GOLD, VMD, CHIMERA, PYMOL

Proficiency in AlphaFold, BindCraft, Rfdiffusion, Protein and Ligand MPNN for protein structure prediction and design

Ulteriori informazioni pertinenti

Programming & Development Skills:

Core Languages: Python, PHP, Perl, Java
Web Development: HTML/CSS/JavaScript, PHP
Machine Learning: TensorFlow, PyTorch, scikit-learn, NumPy, Pandas
Database: MySQL
Version Control: Git, GitHub, Zenodo

High Performance Computing Experience:

Experience with HPC clusters and parallel computing
Job scheduling (SLURM, PBS)
GPU acceleration for ML applications

Research Profiles:

Google Scholar: <https://scholar.google.com/citations?user=JqB6-RcAAAAJ>
ResearchGate: <https://www.researchgate.net/profile/Izaz-Kamal>

Awards & Recognition:

DBT Research Fellowship (2019-2024)
Qualified multiple national-level examinations (DBT JRF, ICMR JRF, GATE, SET)

Additional Technical Expertise:

Statistical analysis (ANOVA, PCA, Regression, multivariate analysis)
Experimental techniques: Western Blotting, UV Spectroscopy, X-ray Crystallography
Custom script development for automation and pipeline optimization

Luogo, data: Kolkata, July 16, 2025

Firma digitale: